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Abstract 
Despite the fact that Alzheimer’s disease (AD) is the most common form of 
dementia, its underlying pathogenesis has not yet fully known. As an intricate and 
multifactorial disease, finding a potential therapy intercepting its pathological 
process is still out of reach. With an increase in evidence of the success of gut 
microbiota modulation as a therapy to other diseases, one should consider the same 
possibility in AD. Therefore, this literature review focuses on exploring the 
possibility of dietary intervention as an innovative therapy for AD by modulating the 
gut microbiota composition based on recent researches. The method used to 
assemble this literature review is by performing a comprehensive literature search 
with corresponding keywords. The result shows that Mediterranean dietary 
intervention, characterized by the high intake of omega-3 polyunsaturated fatty acids, 
antioxidant nutrients, and vitamins, has shown to be beneficial for brain functions 
development which targets the gut-brain axis. However, a higher level of evidence-
based research is still needed to confirm further the findings in hope for a future 
implementation of this new insight as a therapy for AD and to unfold the gut 
microbiota role in it.  
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Introduction 
Alzheimer’s disease (AD) prevalence 
accounts for 50-75% of all forms of 
dementia, making it the most common 
form worldwide.1 In April 2016, the 
World Health Organization (WHO) 
reported that there were 47.5 million 
people suffering from dementia, in 
which the older age group had a 
greater proportion and an impaired 
normal day-to-day activity.2 In 
Indonesia, with a rising number of 
elderly population; 7.6% in 2010 to 
8.03% in 2014 of the total population; 
the estimation of people living with 
AD will be double by the year 2030, 
and reach the sum of 4 million people 
in 2050.3  
Unfortunately, with this alarming rate 
of increase in prevalence, the cause of 
the disease itself has yet to be fully 
elucidated, let alone its therapy. The 
beta-amyloid (Aβ) plaque which 
represents one of the hallmarks of AD 
is believed to be a marker of upstream 
process instead of the cause. On the 
contrary, in cases of AD caused by 
amyloid precursor protein (APP) gene 
mutation, the Aβ plaque buildup is 
considered to be a primary process.4 
With this long-standing debate and the 
fact that AD is a multifactorial 
disease,5 a potential therapy for it is 
still far from being reached. However, 
in the light of other proven therapeutic 
approaches addressing the role of gut 
microbiota in irritable bowel syndrome 
patients, such as fecal microbiota 
transplantation and probiotics, gut 
microbiota modulation could hold 
promising insights to other diseases.6 
Recent studies suggest that gut 
microbiota could play a role in the 
onset of AD through the gut-brain 
axis.7 Aging process characterized by 
chronic pro-inflammatory response 
disrupts the balance and composition 
of gut microbiota.7 This decreased of 
gut microbiota diversity can lead to 
changes in brain function and in host 
behavior.8 Intriguingly, one study has 
proven that antibiotic-induced changes 
of gut microbiota diversity in a murine 
model of AD decreases its Aβ plaque 
deposition.9 
Thus, the focus of this literature review 
is to highlight the intricate relationship 
between gut microbiota and AD 
pathogenesis as well as the possibility 
of gut microbiota composition 
alteration as a potential therapy of AD. 
Materials and Methods 
A comprehensive literature search was 
performed in January 2017 using 
Google Scholar. This database was 
searched with combinations of the 
terms ‘Alzheimer Disease’, ‘Gut 
Microbiota’, ‘Gut-brain axis’ and 
‘Diet’.  
Result and Discussion 
AD Pathogenesis Hypothesis 
AD becomes manifested when genetic, 
lifestyle, and environmental factors 
play their role together, such as 
smoking, obesity, lack of physical 
activity, and certain genes including 
PS1, PS2, and APP genes. That is why 
until now scientists have not fully 
understood the real cause of AD since 
the pathogenesis itself is a complex 
“cascade” which takes place in the 
brain over a long course of time.9  
According to the amyloid cascade 
hypothesis (see Figure 1), the increase 
of Aβ peptide, which is produced via 
altered processing of APP, gives rise to 
a series of events which results in the 
formation of plaques, neurofibrillary 
tangles of hyperphosphorylated tau, 
and neuronal death. Formation of Aβ 
peptide requires β- and γ-secretases, in 
which presenilin proteins (PS1 and 
PS2) play role in catabolizing APP.11 
This neuronal death then causes the 
typical AD clinical dementia 
syndrome.4 Nonetheless, although this 
Aβ plaque buildup is considered as the 
main hallmark of AD, it does not 
always apply to all cases. This was 
already proven through failures of 
most clinical trials which target the 
elimination of Aβ levels.11 One study 
even suggests a shift of perspective, to 
see Aβ plaque buildup as a 
physiological response of the body, 
since in healthy brain, it is needed for 
synaptic plasticity and memory. In this 
new vision, therapy targeting Aβ 
plaque elimination might worsen the 
side effects, making the need of 
finding the true pathogenesis of AD 
become more imperative than ever.12  
Correlation of Gut Microbiota with 
Hypothalamic-pituitary Axis, 
Neurotransmitters, and AD 
The gut is home to most of the 
symbiotic microbes. These microbes 
can be divided into three dominant 
genus, which are Bacteroides, 
Prevotella, and Ruminococcus. Each 
genus has its own metabolism 
properties. Bacteroides are good at 
fermenting carbohydrates and protein. 
Prevotella can degrade plant 
polysaccharides and mucin 
glycoprotein in the gut mucosal layer 
as well as interact with immune 
system. Ruminococcus are great in 
degrading mucins and help epithelial 
cells in sugar uptake.13,14 
Various animal studies have 
discovered that gut microbiota have 
effects on animal’s behavior, including 
anxiety-like behavior and spontaneous 
motor activity. Moreover, it can also 
affect biochemical composition in the 
brain.15 Responsiveness to stress and 
many physiologic activities are 
regulated by hypothalamic-pituitary-
adrenal (HPA) axis, an important part 
in the neuroendocrine system. In the 
germ free mice, there is abnormal 
HPA. However, that abnormalities 
could be reversed by colonization of 
germ free mice with microbiota from 
specific probiotic Bifidobacterium 
infantis. Therefore, gut microbiota has 
influence in regulating the activity of 
HPA and nervous system 
development.16 
Disruption of rapid gut microbiota 
colonization during childhood and 
adolescence can affect the gut-brain 
axis signals and the health in the whole 
life. This condition occurs because 
childhood and adolescence are critical 
periods for brain development. 
Alteration of gut microbiota in the 
adulthood period may also affect the 
brain function and behavior.17 
In addition, disruption in the gut 
barrier can cause disturbance in the 
brain blood barrier. The epithelial 
lining of the mucosal layer of the gut 
are connected through tight junction 
which limits the permeability of the 
gut.18 Disturbance in this structure can 
be caused by inflammation, such as 
those triggered by lipopolysaccharide 
(LPS).19,20 LPS can only enter the 
circulation when there is alteration of 
the tight junction.19 Studies also found 
that LPS can cause prolonged elevation 
of Aβ and hippocampal deficits.20 
Thus, LPS plays a role in Aβ 
accumulation in the brain and AD 
progression.21,22 
Gut microbiota also perform key roles 
in the production of neurotransmitters. 
Some of the neurochemicals we know 
can be synthesized in the gut. For 
example, Lactobacillus brevis and 
Bifidobacterium dentium can produce 
GABA by metabolizing glutamate.23 
The increase of GABA in 
gastrointestinal tract is correlated with 
the increase of GABA in CNS.24,25 
NMDA, a receptor for glutamate, are 
expressed significantly less in germ 
free mice. This indicates that 
disturbance in the gut microbiota can 
decrease the expression of NMDA 
receptor in hippocampus.26 The other 
example is serotonin which is 
synthesized mostly in the gut. The gut 
microbiota plays an important role in 
synthesizing serotonin. Animals and 
human clinical trials suggest that 
selective serotonin reuptake inhibitors 
could reduce the Aβ protein production 
in the brain, indicating that the increase 
of extracellular serotonin levels can 
effectively reduce Aβ plaque formation 
and thereby reduce the risk of AD.27 
Gut microbiota also plays role in 
controlling the gut-brain axis by 
modulating signaling and preserving 
normal gut physiology. The gut-brain 
axis itself has effects on amyloid-
enhancing factors, such as serum 
amyloid A and misfolded Aβ, which 
might be implicated in the onset of 
AD. Therefore, disturbance of gut 
microbiota can increase amyloid 
formation and thus worsen the 
progression of AD.28 
The Normalization of Gut 
Microbiota through the Adherence 
Towards the Mediterranean Diet  
Current available treatments of AD are 
symptomatic and are not used for the 
curative or preventive purposes in the 
progression of AD.29 Moreover, these 
treatments are not universally 
beneficial and some are not considered 
clinically significant.30,31  Given the 
lack of pharmaceutical treatment for 
AD, research invested in the 
modification of lifestyle is currently 
growing.32 It is obvious that diet has an 
important influence on the diversity of 
gut microbiota as the diversity of gut 
microbiota in the host highly depends 
on the food consumed.33,34 Studies 
have shown that the alterations of gut 
microbiota have clear effects on 
intestinal homeostasis, gut 
microbiome, immune system, 
physiology, and host metabolic 
pathways.35 
Among various pattern of diets, one 
dietary intervention that has gained a 
fair amount of interest in Alzheimer's 
research is the Mediterranean diet 
(MD).36 This diet is characterized by 
the daily intake of lots of plant food 
including vegetables, fruits, cereals, 
nuts and beans, moderate intake of 
dairy products, with intake of fatty fish 
and olive oil as the source of fat.37 
Human intervention studies have 
shown that high intake of vegetables, 
fruits, and cereals correlates with the 
significant increase of short chain fatty 
acids, which are very important in the 
regulation of several physiological 
processes.4 
Research shows that MD is beneficial 
in the reduction of inflammation 
biomarkers and in the normalization of 
gut microbiota.38,39 This anti-
inflammatory effects of MD are often 
linked with the changes in the 
composition of gut microbiota, 
including the increase of Bacteroides 
genus and the decrease of Bacillaceae 
genus.36 
The consumption of MD, reflected as 
high intake of omega-3 
polyunsaturated fatty acids which are 
found mainly in the fish and olive oil, 
polyphenols contents in the fruits and 
cereals, antioxidant nutrients, as well 
as vitamins, has been proven vital for 
neuronal and brain functions 
development and are able to enhance 
healthy gut microbiota.40-42  
Several studies also suggest that MD 
may delay cognitive decline.42,43 
Although these lines of studies mostly 
are resting exclusively on 
epidemiological studies which link 
nutritional factors with AD, the 
biomarker findings provide biological 
evidence which further support those 
studies. Lower adherence to the MD 
was related to the increased atrophy of 
the key brain regions for AD among 
cognitively normal individuals, as 
depicted in the study of Mosconi L, et 
al45 through the results of MRI scans 
of the subject representative of the 
lower versus higher adherence to the 
MD. 
Conclusion 
In spite of the increasing rate of the 
prevalence of AD, the cause of the 
disease itself remains a mystery, and so 
does its therapy. Recent studies 
suggest that gut microbiota might play 
a role in the onset of AD through the 
gut-brain axis. Mediterranean Diet has 
been shown to delay cognitive decline 
among AD patients. Both of these 
findings further suggest the potential 
approach for the treatment of AD 
through the modulation of gut 
microbiota which can be achieved 
through the adherence to 
Mediterranean Diet. 
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Figure 1. Amyloid cascade 
hypothesis.46 
